肠杆菌目对新型抗革兰阴性菌药物的耐药机制
本文为综述,检索PubMed截至2025年6月30日的英文文献,分析肠杆菌目对二氮杂双环辛烷类、双环硼酸类、头孢吡肟/恩美唑巴坦、头孢地尔和依拉环素的耐药机制。理解这些机制对重新设计治疗策略和未来抗生素研发至关重要。
要点
- 肠杆菌目对新型β-内酰胺酶抑制剂复合制剂及新抗菌药已出现耐药机制。
- 耐药机制涉及二氮杂双环辛烷类、双环硼酸类、头孢地尔和依拉环素等。
- 阐明耐药机制有助于优化治疗策略和指导未来抗生素设计。
核心结论
- 理解微生物对新型抗菌药或抑制剂组合的耐药机制,对重新设计治疗策略和未来抗生素设计至关重要。
研究设计与样本
- 综述,检索PubMed截至2025年6月30日的相关英文文献,并纳入作者已知文献。
主要发现
- 分析了肠杆菌目对二氮杂双环辛烷类、双环硼酸类、头孢吡肟/恩美唑巴坦、头孢地尔和依拉环素的耐药机制。
- 总结了近期引入的β-内酰胺酶抑制剂家族(包括二氮杂双环辛烷类和双环硼酸类)以及其他新型组合或抗菌药的主要耐药机制。
临床怎么用
- 临床应认识肠杆菌目对新型药物可能存在的耐药机制,以合理设计治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The emergence of multidrug-resistant Gram-negative bacteria poses a significant threat to global health. This has prompted the development of novel antimicrobials and combinations with β-lactamase inhibitors. OBJECTIVES: This review aims to shed light on the resistance mechanisms associated with new drugs against Enterobacterales. SOURCES: We searched PubMed relevant English literature in up to 30 June 2025, as well as including articles known to the authors. We analysed Enterobacterales resistance mechanisms for diazabicyclooctanes, bicyclic boronates, cefepime/enmetazobactam, cefiderocol, and eravacycline. CONTENT: The review summarises the main mechanisms of resistance to recently introduced ß-lactamase inhibitor families, including diazabicyclooctanes and bicyclic boronates, as well as other novel combinations or antimicrobials, such as cefiderocol and eravacycline. IMPLICATIONS: Understanding how microorganisms develop resistance to new antimicrobials or combinations with inhibitors is essential for redesigning treatment strategies and for the design of future antibiotics.
引用
- Delgado-Valverde M, Perez-Palacios P, López-Cerero L, et al. Mechanisms of resistance to newer drugs against gram negative bacteria in enterobacterales. Clin Microbiol Infect. 2026. PMID: 41513038. doi:10.1016/j.cmi.2025.12.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。